Adocia SA (ADOC.PA)

5,20 +0,24 (+4,84 %) À la clôture : 05:35PM CEST

Adocia SA

115 Avenue Lacassagne
Lyon 69003
France
33 4 72 61 06 10
https://www.adocia.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 103

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Gérard Soula	Co-Founder, Chairman, CEO, Pres and Interim Director of Bus. Devel. & Legal	487,04k	S.O.	1945
Mr. Olivier Soula M.B.A., Ph.D.	Co-Founder, Deputy GM, VP, Director of R&D and Director	344,04k	S.O.	1970
Ms. Valérie Danaguezian	CFO and Admin. & Financial Director	S.O.	S.O.	S.O.
Ms. Geraldine Favre Soula	HR Devel. Director	S.O.	S.O.	S.O.
Dr. Bertrand Alluis	Head of the Analysis Department and Project Mang.	S.O.	S.O.	S.O.
Dr. David Duracher	Head of the Pharmaceutical Devel. & Physical Chemistry Departments and Project Mang.	S.O.	S.O.	S.O.
Dr. Richard Charvet	Head of Chemistry Department & Project Mang.	S.O.	S.O.	S.O.
Dr. Grégory Meiffren	Head of the Biology Department & Project Mang.	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2021 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en EUR.

Description

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform is designed and developed to optimize the performance of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes bi-hormonal products, which include BioChaperone AsPram, which is a combination of rapid insulin aspart with pramlintide; and BioChaperone Glargine Liraglutidea, which is a fixed combination of insulin glargine with an analogue of the GLP-1 receptor. In addition, the company's preclinical pipeline includes multihormonal products for the treatment of obesity, including BioChaperone GluExe, which is a combination of glucagon and exenatide; PramExe, which is a combination of pramlintide and exenatide; and BioChaperone PramGluExe, which is a triple combination of pramlintide, glucagon and exenatide. It has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. The company was incorporated in 2005 and is headquartered in Lyon, France.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Adocia SA en date du 31 juillet 2022 est 9. Les scores principaux sont Audit : 9; Société : 9; Droits des actionnaires : 9; Compensation : 9.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.